ACT for Syndromic and Subsyndromic Depression in Bipolar Disorder
Acceptance and Commitment Therapy for Individuals With Syndromic and Subsyndromic Depression in Bipolar Mood Disorder: A Controlled and Randomized Clinical Trial
1 other identifier
interventional
42
1 country
1
Brief Summary
The goal of this clinical trial is to test the efficacy of Acceptance and Commitment Therapy (ACT) as a psychotherapeutic treatment for patients with Bipolar Disorder (BD). The following questions will be investigated:
- The efficacy of ACT in reducing depressive symptoms in patients with BD.
- The efficacy of ACT in improving the quality of life in patients with BD.
- The efficacy of ACT in improving functionality in patients with BD.
- The efficacy of ACT in improving sleep quality in patients with BD.
- The efficacy of ACT in improving psychological flexibility in patients with BD Participants in the clinical group will undergo 12, 2 hours, weekly sessions of Acceptance and Commitment Therapy, in addition to their regular pharmacological treatment. Participants in the control group will undergo 3, 2 hours, weekly sessions of Bipolar Disorder Psychoeducation Therapy, in addition to their regular pharmacological treatment. Scales and assessments will be used to measure study outcomes on 5 different time-points: pre-intervention (month 0), post-intervention (month 3), follow-up 1 (month 6), follow-up 2 (month 9), follow-up 3 (month 12). Mood scales will be assessed every 2 weeks for the duration of treatment and every 4 weeks during the additional 12 week follow-up period. Results will be compared among both groups to assess the effectiveness of Acceptance and Commitment Therapy as an intervention for syndromic and sub-syndromic depression in bipolar disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2024
CompletedFirst Posted
Study publicly available on registry
April 15, 2024
CompletedStudy Start
First participant enrolled
May 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedApril 3, 2025
March 1, 2025
1.6 years
April 3, 2024
March 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Montgomery-Asberg Depression Scale
Minimum value: 0 (better) Maximum value: 60 (worse)
Baseline, during treatment every 2 weeks, post-treatment (week 12), in between assessments every 4 weeks, and follow-ups (6, 9 and 12 months)
Young Mania Rating Scale
Minimum value: 0 (better) Maximum value: 54 (worse)
Baseline, during treatment every 2 weeks, post-treatment (week 12), in between assessments every 4 weeks, and follow-ups (6, 9 and 12 months)
Secondary Outcomes (4)
Functional Assessment Staging Tool
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
World Health Organization Quality of Life Brief Scale
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Pittsburgh Sleep Quality Index
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Psychological Flexibility Questionnaire
Baseline, during treatment weekly, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Other Outcomes (3)
Generalized Anxiety Disorder 7-item Scale
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Medication Recommendation Tracking Form
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Regulatory Satisfaction Alertness Timing Efficiency Duration
Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)
Study Arms (2)
Acceptance and Commitment Therapy
EXPERIMENTALParticipants in the clinical group will receive usual pharmacological treatment and undergo a protocol of 12 Acceptance and Commitment Therapy sessions, in group format, during 3 months. The intervention will be held weekly, with an estimated duration of 2 hours for each session, in addition to the participants' regular drug treatment. Scales are administered at the beginning and end of treatment, with follow-ups after 6, 9 and 12 months.
Psychoeducation
EXPERIMENTALParticipants in the control group will usual pharmacological treatment and 3 sessions of Psychoeducation, in group format. Scales are administered at the beginning and end of treatment, with follow-ups after 6, 9 and 12 months.
Interventions
The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.
The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.
Eligibility Criteria
You may qualify if:
- Diagnosis of Bipolar Disorder type I and II according to DSM V
- Presence of depressive symptoms (MADRS\>12)
- Not undergoing psychotherapy
- Availability to attend in-person group therapy sessions
- Signing consent form
You may not qualify if:
- Organic mental disorder
- Presence of manic or hypomanic symptoms (YMRS\>12)
- Currently undergoing psychotherapy (not able to pause during the study)
- Major medication change in last 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beny Laferlead
Study Sites (1)
Tatiana Cohab Khafif
São Paulo, São Paulo, 01231010, Brazil
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Beny Lafer, MD PhD
University of Sao Paulo
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 3, 2024
First Posted
April 15, 2024
Study Start
May 6, 2024
Primary Completion
December 1, 2025
Study Completion (Estimated)
December 1, 2026
Last Updated
April 3, 2025
Record last verified: 2025-03